IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ (OISTER)
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients presenting with ACS (Acute Coronary Syndrome) in the emergency department will be screened for clinical eligibility and asked to sign informed consent to the study.
A total of 40 patients will be randomized. 20 of them will receive a Trapidil eluting stent (Intrepide™ stent), 20 will receive a Paclitaxel eluting stent (Taxus™ stent). After 90 days the patients who were treated with the INTREPIDE stent in the first lesion will be treated with the Taxus stent in the second lesion. After 90 days the patients who were treated with the Taxus stent in the first lesion will be treated with the INTREPIDE stent in the second lesion.
Coronary angiography will be performed through the femoral (groin) or radial (wrist) artery with the use of standard techniques. The doctor will determine if the patient is qualified for enrolment at the end of the diagnostic coronary angiogram
| Condition | Intervention | Phase |
|---|---|---|
| Coronary Artery Disease Acute Coronary Syndrome | Device: Intrepide Trapidil eluting stent Device: Taxus drug eluting stent | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single (Participant) Primary Purpose: Treatment |
| Official Title: | OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™ |
- To compare stent re-endothelialization using Trapidil drug eluting stent versus Taxus paclitaxel eluting stent at 3 months after intervention. The primary endpoint will be defined by % of stent struts neointimal coverage at 90 days [ Time Frame: 3 months ]
- In-stent binary angiographic restenosis and in-stent late lumen loss; in segment late loss; assessed by quantitative computed angiography (QCA) at 12 months [ Time Frame: 12 months ]
| Estimated Enrollment: | 40 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Intrepide
Group A- Primary stenting with Intrepide trapidil eluting stent
|
Device: Intrepide Trapidil eluting stent
The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD. The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia. |
|
Experimental: Taxus
Group B Stenting with Taxus DES
|
Device: Taxus drug eluting stent
Paclitaxel Drug eluting stent manufactured by Boston Scientific
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Clinical
- >18 years of age,
- symptoms of non ST-elevation ACS (defined by the ACC/AHA criteria) for 30 min but <48 h
- Patient must provide written informed consent prior to the procedure using a form that is approved by the local Institutional Review Board
Angiographic
- reference vessel diameter of culprit/target lesion between 2.25 to 3.5 mm (visual estimate)
- discrete target lesion (maximum length of 28 mm by visual estimation)
- target lesion is in a native coronary artery
- presence of another lesion more than 70% in a vessel different from the culprit one amenable of planned percutaneous treatment 90 days thereafter.
Exclusion Criteria:
Clinical
- previously documented left ventricular ejection fraction of less than 30%
- estimated life expectancy of less than 12 months
- a history of bleeding diathesis, leukopenia, thrombocytopenia, or severe hepatic or renal dysfunction
- participation in another study
- inability to give informed consent owing to prolonged cardiopulmonary resuscitation
- and dominant Renal impairment (serum creatinine > 2.0 mg/dl) Angiographic
- non-culprit lesion located in the proximal LAD or in a proximal and dominant Circumflex artery
- previous PCI of the target vessels restenosis or stent thrombosis as culprit lesion
- unprotected left main coronary artery disease
- non-culprit lesion located in a vein graft
- severe multivessel disease (three major epicardial vessel disease) need of overlapping stenting for one lesion
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00914420
| Italy | |
| University Hospital Modena | Recruiting |
| Modena, Italy | |
| Contact: Giuseppe M Sangiorgi, MD sangiorgi.giuseppe@policlinico.mo.it | |
| Principal Investigator: Giuseppe Sangiorgi, MD | |
| Principal Investigator: | Antonio Columbo, MD | San Raffaele hospital, Milano |
| Principal Investigator: | Giuseppe M Sangiorgi, MD | University Hospital Modena Italy |
More Information
Additional Information:
| Responsible Party: | Dr Giuseppe Sangiorgi Dr Antonio Colombo, University Hospital Modena - Italy ; Raffaele hospital, Milano- Italy |
| ClinicalTrials.gov Identifier: | NCT00914420 History of Changes |
| Other Study ID Numbers: |
CST10 |
| Study First Received: | June 3, 2009 |
| Last Updated: | April 16, 2010 |
Keywords provided by Clearstream Technologies Ltd.:
|
OCT Reendothelialisation Intrepide Trapidil Taxus |
Additional relevant MeSH terms:
|
Syndrome Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Disease Pathologic Processes Heart Diseases Cardiovascular Diseases |
Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Trapidil Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Vasodilator Agents |
ClinicalTrials.gov processed this record on August 23, 2017